Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
Soleno Therapeutics Inc (NASDAQ: SLNO) closed the day trading at $43.54 down -7.10% from the previous closing price of $46.87. In other words, the price has decreased by -$7.10 from its previous closing price. On the day, 5.39 million shares were traded. SLNO stock price reached its highest trading level at $46.1457 during the session, while it also had its lowest trading level at $42.11.
Ratios:
For a better understanding of SLNO, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.88 and its Current Ratio is at 16.08. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on October 07, 2025, initiated with a Buy rating and assigned the stock a target price of $125.
On August 20, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $123.
On June 23, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $110.TD Cowen initiated its Buy rating on June 23, 2025, with a $110 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’25 when Abingworth Bioventures VII LP bought 1,347,522 shares for $82.15 per share.
Hirano Patricia C sold 3,830 shares of SLNO for $316,971 on Jul 01 ’25. The insider now owns 13,206 shares after completing the transaction at $82.76 per share. On Jul 01 ’25, another insider, PATRICIA HIRANO, who serves as the Officer of the company, bought 3,830 shares for $82.76 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLNO now has a Market Capitalization of 2338534400 and an Enterprise Value of 1891987072. For the stock, the TTM Price-to-Sale (P/S) ratio is 23.70 while its Price-to-Book (P/B) ratio in mrq is 4.73. Its current Enterprise Value per Revenue stands at 19.174 whereas that against EBITDA is -23.0.
Stock Price History:
The Beta on a monthly basis for SLNO is -3.11, which has changed by -0.17843997 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, SLNO has reached a high of $90.32, while it has fallen to a 52-week low of $41.50. The 50-Day Moving Average of the stock is -30.57%, while the 200-Day Moving Average is calculated to be -35.11%.
Shares Statistics:
Over the past 3-months, SLNO traded about 1.99M shares per day on average, while over the past 10 days, SLNO traded about 2329770 shares per day. A total of 53.70M shares are outstanding, with a floating share count of 46.01M. Insiders hold about 13.42% of the company’s shares, while institutions hold 98.75% stake in the company. Shares short for SLNO as of 1760486400 were 8435433 with a Short Ratio of 4.24, compared to 1757894400 on 7246780. Therefore, it implies a Short% of Shares Outstanding of 8435433 and a Short% of Float of 18.120001.
Earnings Estimates
Investors are keenly observing as 2.0 analysts analyze and rate. The current performance of Soleno Therapeutics Inc (SLNO) in the stock market.The consensus estimate for the next quarter is $0.35, with high estimates of $0.88 and low estimates of -$0.34.
Analysts are recommending an EPS of between $0.22 and $0.2 for the fiscal current year, implying an average EPS of $0.21. EPS for the following year is $2.95, with 11.0 analysts recommending between $5.78 and $1.01.
Revenue Estimates
For the next quarter, 4 analysts are estimating revenue of $78.2M. There is a high estimate of $108.18M for the next quarter, whereas the lowest estimate is $44.32M.
Based on 11 analysts’ estimates, the company’s revenue will be $414.05M in the next fiscal year. The high estimate is $563M and the low estimate is $252.18M.
